Stamford, CTCIK 19209384 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
68 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Caris Life Sciences Inc | 7.82M | $210.88M | 8.1% | +500.0K | Added |
| 2 | Edgewise Therapeutics Inc | 5.21M | $129.31M | 5.0% | 0 | Held |
| 3 | Neurocrine Biosciences Inc | 751.5K | $106.59M | 4.1% | −128.7K | Reduced |
| 4 |
| 922.0K |
| $104.10M |
| 4.0% |
| +141.8K |
| Added |
| 5 | Nuvalent Inc | 821.4K | $82.63M | 3.2% | −191.6K | Reduced |
| 6 | Xenon Pharmaceuticals Inc | 1.83M | $81.80M | 3.1% | −1.78M | Reduced |
| 7 | Cg Oncology Inc | 1.87M | $77.67M | 3.0% | −1.41M | Reduced |
| 8 | Hinge Health Inc | 1.30M | $60.60M | 2.3% | +394.1K | Added |
| 9 | Align Technology Inc | 381.0K | $59.49M | 2.3% | −28.7K | Reduced |
| 10 | Kodiak Sciences Inc | 2.07M | $57.96M | 2.2% | +2.07M | New |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio